Endeavor BioMedicines Raises $132.5 Million in Oversubscribed Series C Financing Led by AyurMaya to Advance Pipeline of Transformational Medicines
Endeavor BioMedicines Raises $132.5 Million in Oversubscribed Series C Financing Led by AyurMaya to Advance Pipeline of Transformational Medicines
04/24/24, 11:39 AM
Location
san diegoMoney raised
$133 million
Round Type
series c
Investors
T. Rowe Price Associates, Silver Arch Bio, Piper Heartland Healthcare Capital, Perceptive Advisors, Omega Funds, Longitude Capital, Eckuity Capital, Avidity Partners, Ally Bridge Group, Abrdn Inc., Woodline Partners, Velosity Capital, Sym Biosis, Invus, Fidelity Management & Research Company, Matrix Capital Management, Ayur Maya
Endeavor BioMedicines, Inc. has closed a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument. The oversubscribed round was led by AyurMaya, an affiliate of Matrix Capital Management, with participation from new investors including Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital, and Woodline Partners; and strong support from existing investors.
Company Info
Location
12707 high bluff dr., suite 300
san diego, california, united states
Additional Info
Endeavor BioMedicines is a clinical stage company targeting the drivers of fibrosis and oncology. We combine best-in-class therapeutics with an evolving understanding of terminal diseases to develop medicines with the potential to reverse severe health conditions. Our lead program, ENV-101, is a Hedgehog signaling inhibitor with demonstrated clinical activity that we are investigating in IPF. At Endeavor, we are an innovative and focused team that has come together to live up to our name and bold mission: to help patients feel better and live longer.